Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)
Thromboembolism · children and adolescents (< 18 years of age) with first‐line ALL
The review found no eligible studies for this question.
1 finding from 1 review
- PEG‐asparaginase treatment regimens for acute lymphoblastic leukaemia in children: a network meta‐analysis 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found